

# Hypoxia Upregulates Glucose Transport Activity Through an Adenosine-Mediated Increase of GLUT1 Expression in Retinal Capillary Endothelial Cells

Hitoshi Takagi, George L. King, and Lloyd Paul Aiello

Elevation of intracellular glucose within retinal vascular cells is believed to be an important causal factor in the development of diabetic retinopathy. The intracellular glucose concentration is regulated by both the rate of glucose metabolism and glucose transport. Because retinal hypoxia often precedes proliferative diabetic retinopathy, we have studied the regulation of the glucose transport system by hypoxia in cultured bovine retinal endothelial cells (BRECs). Because retinal ischemia is known to increase intracellular adenosine levels, which subsequently regulate hypoxia-inducible genes, such as vascular endothelial growth factor and erythropoietin, the role of adenosine and its receptor-mediated pathways has also been evaluated. Hypoxia (0.5% O<sub>2</sub>, 5% CO<sub>2</sub>, and 94.5% N<sub>2</sub>) stimulated GLUT1 mRNA expression in BRECs in a time-dependent manner with an 8.9 ± 1.5-fold ( $P < 0.01$ ) increase observed after 12 h. GLUT1 mRNA expression returned to baseline (1.4 ± 0.3-fold of control) within 12 h after reinstatement of normoxia. N<sup>6</sup>-Cyclopentyl adenosine (adenosine A<sub>1</sub> receptor agonist, K<sub>d</sub> = 1 nmol/l) did not affect GLUT1 mRNA expression at concentrations up to 1 μmol/l, while 2-*p*-(2-carboxyethyl)-phenethyl-amino-5'-*N*-ethylcarboxamido-adenosine and 5'-(*N*-ethylcarboxamido)-adenosine (adenosine A<sub>2</sub> receptor [A<sub>2</sub>R] agonists, K<sub>d</sub> = 15 and 16 nmol/l, respectively) increased mRNA levels at concentrations as low as 10 nmol/l. Maximal stimulation was 2.3 ± 0.2- and 2.1 ± 0.2-fold, respectively ( $P < 0.01$ ). The adenosine A<sub>2a</sub> receptor antagonist 8-(3-chlorostyryl)caffeine (CSC) (K<sub>d</sub> = 100 nmol/l for A<sub>2</sub>R) inhibited hypoxia-stimulated GLUT1 mRNA expression by 40 ± 8% at 100 nmol/l. Hypoxia upregulated GLUT1 protein expression by 3.0 ± 0.3-fold after 12 h ( $P < 0.01$ ), but this response was attenuated by CSC ( $P < 0.05$ ). Hypoxia increased

glucose transport activity by 2.1 ± 0.3-fold ( $P < 0.001$ ) after 12 h, a response inhibited 65% by CSC ( $P < 0.01$ ). A protein kinase A (PKA) inhibitor (H89, 20 μmol/l) suppressed hypoxia-induced GLUT1 mRNA expression by 42 ± 9% ( $P < 0.01$ ). These data suggest that hypoxia in BRECs upregulates glucose transport activity through an increase of GLUT1 expression that is partially mediated by adenosine, A<sub>2</sub>R, and the cAMP-PKA pathway. *Diabetes* 47:1480–1488, 1998

**R**etinopathy is a major complication of diabetes mellitus often resulting in visual loss. Previous epidemiological studies (1,2) and clinical trials (3) have demonstrated that hyperglycemia is an important causal factor for the initiation and progression of microvascular dysfunction, including diabetic retinopathy. Multiple hypotheses, including nonenzymatic protein glycosylation, changes in polyol pathway activity, and alterations in diacylglycerol and protein kinase C (PKC) levels, have been suggested as common mechanisms underlying the diverse vascular complications of diabetes (4–7). Two of the classic complications of diabetic retinopathy involve proliferation of endothelial cells and increased retinal vascular permeability. Because intracellular glucose concentration is at least partially regulated by glucose transport activity, and because retinal endothelial cells play a central role in maintaining retinal blood barrier function (8,9), alterations of the glucose transport system in these cells might be involved in the pathogenesis of diabetic retinopathy.

Retinal hypoxia due to progressive retinal nonperfusion is a hallmark of diabetic retinopathy and is at least partially responsible for the development of intraocular neovascularization and increased retinal vascular permeability. Although cellular hypoxia has been reported to correlate with increased glucose uptake due to elevated glucose transporter mRNA and posttranslational alterations (10–14), the mechanisms responsible for the hypoxia-induced regulation of the glucose transport system in retinal vascular cells is incompletely understood.


Adenosine concentrations markedly increase under hypoxic conditions, mainly as a result of decreased recycling of adenosine to AMP by adenosine kinase (15). Indeed, retinal ischemia increases retinal adenosine concentrations in a porcine model (16). Previously, we have reported that hypoxia regulates the expression of vascular endothelial growth factor (VEGF) and its receptor (kinase insert domain-containing receptor [KDR]) through an increase in adenosine and subse-

From the Research Division (H.T., G.L.K., L.P.A.) and Beetham Eye Institute (L.P.A.), Joslin Diabetes Center; the Departments of Ophthalmology (L.P.A.) and Medicine (G.L.K.), Harvard Medical School; and the Department of Medicine (G.L.K.), Brigham and Women's Hospital, Boston, Massachusetts.

Address correspondence and reprint requests to Lloyd Paul Aiello, MD, PhD, Beetham Eye Institute, Joslin Diabetes Center, One Joslin Pl., Boston, MA. E-mail: aiello@joslab.harvard.edu.

Received for publication 23 January 1998 and accepted in revised form 23 April 1998.

A<sub>1</sub>R, A<sub>2a</sub>R, A<sub>2b</sub>R, A<sub>2</sub>R, adenosine receptors; ARE, adenylate-uridylylate-rich RNA element; BREC, bovine retinal endothelial cell; BSA, bovine serum albumin; CGS21680, 2-*p*-(2-carboxyethyl)-phenethyl-amino-5'-*N*-ethylcarboxamido-adenosine; CPA, N<sup>6</sup>-cyclopentyl adenosine; CSC, 8-(3-chlorostyryl)caffeine; DSS, disuccinimidylsuberate; GFX, GF 109203X; H89, N-[2-(*p*-bromocinnamyl)amino]ethyl]-5-isoquinolinesulfonamide; IC<sub>50</sub>, inhibitory concentration 50; KDR, kinase insert domain-containing receptor; KRBP, Krebs-Ringer phosphate buffer; NECA, 5'-(*N*-ethylcarboxamido)-adenosine; PBS, phosphate-buffered saline; PBS-T, phosphate-buffered saline with 0.1% Tween-20; PKA, protein kinase A; PKC, protein kinase C; UTR, untranslated region; VEGF, vascular endothelial growth factor.



**FIG. 1.** Hypoxia upregulates GLUT1 mRNA expression. BRECs were exposed to 0.5% oxygen, 5% CO<sub>2</sub>, and 94.5% N<sub>2</sub> for the duration indicated. A representative Northern blot using GLUT1 cDNA and control 36B4 probe (A) and quantitation of multiple experiments after normalization to the control signal (B) are shown. Results are expressed as normalized GLUT1 mRNA expression (percent of normoxic control  $\pm$  SD). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .

quent activation of the cAMP-protein kinase A (PKA) pathway by the adenosine A<sub>2</sub> receptor (A<sub>2</sub>R) (17,18). Erythropoietin, whose expression is regulated by hypoxia in a similar manner (19), is also induced by adenosine through the A<sub>2</sub>R (20).

In the present study, we have examined the hypothesis that hypoxia can upregulate the glucose transport system in microvascular bovine retinal endothelial cells (BRECs). Because retinal hypoxia is a major component of diabetic retinopathy, and because adenosine and its receptors have been shown to mediate hypoxic effects in other systems, we have investigated the hypoxia-induced regulation of GLUT1 and evaluated the role of adenosine, its receptors, and PKA in mediating this response. We find that hypoxia increases GLUT1 mRNA concentration, protein expression, and activity through an adenosine-mediated mechanism involving the A<sub>2</sub>R and the cAMP-PKA pathway.

## RESEARCH DESIGN AND METHODS

**Materials.** Plasma-derived horse serum was obtained from HyClone (Logan, UT). N<sup>6</sup>-Cyclopentyl adenosine (CPA), 5'-(N-ethylcarboxamido)-adenosine (NECA), 2-*p*-(2-carboxyethyl)-phenethyl-amino-5'-N-ethylcarbox-amidoadenosine (CGS21680), and 8-(3-chlorostyryl)caffeine (CSC) were purchased from Research International Biochemicals (Natick, MA). GF 109203X (GFX) and N-[2-((*p*-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide (H89) were purchased from Calbiochem (La Jolla, CA). Adenosine deaminase was purchased from

Worthington Biochemicals (Freehold, NJ). <sup>3</sup>H-Deoxyglucose and [<sup>32</sup>P]dATP were obtained from Amersham (Arlington Heights, IL). Human GLUT1 cDNA was provided by Dr. Barbara M. Kern. Rabbit polyclonal anti-GLUT1 antibody was purchased from Chemicon (Temecula, CA).

**Cell cultures.** Primary cultures of BRECs were isolated by homogenization and a series of filtration steps as previously described (21). Primary BRECs were grown on fibronectin- (NY Ben Reagents, New York Blood Center, NY) coated dishes (Costar, Cambridge, MA) containing Dulbecco's modified Eagle's medium with 5.5 mmol/l glucose, 10% plasma-derived horse serum, 50 mg/l heparin, and 50 U/l VEGF (Boehringer Mannheim, Indianapolis, IN). Cells were cultured in 5% CO<sub>2</sub> at 37°C, and media were changed every 3 days. Endothelial cell homogeneity was confirmed by immunoreactivity with anti-factor VIII antibodies analyzed by confocal microscopy. After the cells reached confluence, the medium was changed every 3 days, and only cells from passage 7–11 were used for experiments.

**Hypoxia studies.** Confluent cell monolayers were exposed to 0.5% O<sub>2</sub>, 5% CO<sub>2</sub>, and 94.5% N<sub>2</sub> using a Lab-Line Advanced Computer-Controlled Infrared Water-Jacked CO<sub>2</sub> Incubator with reduced oxygen control (model 480; Melrose Park, IL). All cells were maintained at 37°C in a constant 5% CO<sub>2</sub> atmosphere with oxygen deficit induced by nitrogen replacement. Cells cultured under these conditions showed no morphological changes by light microscopy after exposures exceeding 72 h, excluded Trypan Blue dye (>98%), and can be subsequently passaged normally. These conditions have been previously shown to invoke hypoxia-mediated responses in these cells and to correspond to in vivo hypoxic conditions (31). Cells incubated under standard normoxic conditions from the same batch and passage were used as controls (95% air, 5% CO<sub>2</sub>).

**Northern blot analysis.** Total RNA was isolated from individual P-100 tissue culture plates using guanidium thiocyanate (22). Northern blot analysis was performed on 20–25  $\mu$ g total RNA after 1% agarose-2 mol/l; formaldehyde gel electrophoresis and subsequent capillary transfer to Biotrans nylon membranes (ICN Biochemicals, Irvine, CA) and ultraviolet crosslinking using a Stratagene UV Stratalinker 2400 (La Jolla, CA). Radioactive probes were generated using Amersham Multiprime labeling kits and [<sup>32</sup>P]dATP. Blots were prehybridized, hybridized, and washed in 0.5  $\times$  sodium chloride-sodium citrate and 5% SDS at 65°C with four changes over 1 h in a rotating hybridization oven (Robbins Scientific Model 400, Sunnyvale, CA). All signals were analyzed using Molecular Dynamics Computing Densitometer and PhosphorImager (Mountain View, CA), and lane loading differences were normalized using 36B4 cDNA probe.


**Western blot analysis.** After incubation, cells were solubilized in 100  $\mu$ l of lysis buffer (1% Triton X-100, 50 mmol/l HEPES, 10 mmol/l EDTA, 10 mmol/l sodium pyrophosphate, 100 mmol/l sodium fluoride, 1 mmol/l sodium orthovanadate, 10  $\mu$ g/ml aprotinin, 10  $\mu$ g/ml leupeptin, and 2 mmol/l phenylmethylsulfonyl fluoride) and clarified by 3 min of centrifugation at 12,000 rpm. After determining protein concentration using the Bio-Rad Protein Assay (Richmond, CA), equal amounts of protein were subjected to SDS electrophoresis under reduced conditions (15 mg/ml dithiothreitol) and electrically transferred to nitrocellulose membrane (Schleicher & Schuell, Keene, NH). We used 10% gels to separate proteins. After blocking with phosphate-buffered saline (PBS) with 0.1% Tween-20 (PBS-T; Bio-Rad), including 3% bovine serum albumin (BSA) (Arnel Products, New York, NY) for 2 h at room temperature, filters were incubated with anti-GLUT1 antibody for 1.5 h at room temperature. After washing with PBS-T, filters were incubated with <sup>125</sup>I-labeled protein A for 1 h. The signals were detected using Molecular Dynamics Computing Densitometer and PhosphorImager.

**Glucose uptake studies.** BRECs cultured on 12-well cluster dishes were washed with Krebs-Ringer phosphate buffer (KRPB) (136 mmol/l NaCl, 4.7 mmol/l KCl, 10 mmol/l NaPO<sub>4</sub>, 0.5 mmol/l MgCl<sub>2</sub>, and 1 mmol/l CaCl<sub>2</sub>) with 0.2% BSA two times and incubated in KRPB for 20 min. Cells were then incubated in KRPB containing 0.5  $\mu$ Ci/ml <sup>3</sup>H-deoxyglucose and cold 1 mmol/l 2-deoxyglucose for 5 min. The reaction was terminated by placing the plates on ice and adding ice-cold PBS. After three washes with PBS, the cells were dissolved in 0.1% SDS. Aliquots of each sample were mixed with scintillant (Universal zol; ICN) and counted by a scintillation counter. Protein measurement was performed using the BCA protein assay kit (Bio-Rad, Hercules, CA).

**Statistical analysis.** Determinations were performed in triplicate, and experiments were repeated at least three times. Results are expressed as means  $\pm$  SD unless otherwise indicated. Statistical analysis used the unpaired Student's *t* test to compare quantitative data populations with normal distributions and equal variance. Data were analyzed using the Mann-Whitney rank-sum test for populations with nonnormal distributions or unequal variance. A *P* value of <0.05 was considered statistically significant.

## RESULTS

**Hypoxia upregulates GLUT1 mRNA expression.** To investigate the effect of hypoxia on GLUT1 mRNA expression in BRECs, Northern blot analysis was performed on BRECs



**FIG. 2.** Hypoxia-induced GLUT1 mRNA expression is reversed by reinstatement of normoxia. Cells were exposed to 18 h of hypoxia followed by the reinstatement normoxia (95% air, 5% CO<sub>2</sub>) for the duration indicated. **A** representative Northern blot using GLUT1 cDNA and control 36B4 probe (**A**) and quantitation of multiple experiments after normalization to the control signal (**B**) are shown.

exposed to a mixture of 0.5% O<sub>2</sub>, 5% CO<sub>2</sub>, and 94.5% N<sub>2</sub> (Fig. 1). Hypoxia stimulated GLUT1 mRNA expression in BRECs in a time-dependent manner with an initial statistically significant increase observed after 3 h ( $P < 0.05$ ) and elevated expression maintained for over 24 h. Maximal hypoxia-induced GLUT1 mRNA expression of  $8.9 \pm 1.5$ -fold ( $P < 0.01$ ) was observed after 12 h. Elevated expression was maintained over 36 h (data not shown).

**Hypoxia-induced GLUT1 mRNA expression is reversed by reinstatement of normoxia.** The response of hypoxia-induced GLUT1 mRNA expression to reinstatement of normoxia was assessed by returning cells to normal oxygen conditions after 18 h of hypoxic exposure (Fig. 2). Hypoxia increased GLUT1 mRNA  $8.3 \pm 1.9$ -fold ( $P < 0.01$ ). Reinstatement of normoxia for 12 and 24 h reduced GLUT1 mRNA levels to  $1.4 \pm 0.3$ - and  $1.0 \pm 0.1$ -fold of control, respectively ( $P < 0.01$ ). Neither of these two conditions were significantly different from control levels.

**Adenosine receptor agonists increase GLUT1 mRNA expression.** Because it is well documented that hypoxia increases intracellular adenosine levels (15,16), we investigated whether adenosine analogs could mimic the hypoxia-induced increase of GLUT1 mRNA. CPA is a stable adenosine A<sub>1</sub> receptor (A<sub>1</sub>R) agonist whose inhibitory concentration 50 (IC<sub>50</sub>) for A<sub>1</sub>R and for A<sub>2</sub>R binding is  $\sim 1.0$  and 600 nmol/l, respectively (23,24). Exposure to CPA for 24 h did not affect

GLUT1 mRNA expression at concentrations up to 1,000 nmol/l, but it did increase mRNA expression at higher concentrations (Fig. 3A). Stimulation of cells with 50  $\mu$ mol/l CPA increased mRNA levels  $160 \pm 36\%$  ( $P < 0.01$ ). Induction of GLUT1 mRNA expression by high-dose CPA (50  $\mu$ mol/l) was initially observed after 12 h (data not shown).

Because CPA at concentrations ( $< 1,000$  nmol/l) that selectively stimulate A<sub>1</sub>R (24) did not increase GLUT1 mRNA levels, and because higher doses can stimulate both A<sub>1</sub>R and A<sub>2</sub>R, we investigated whether adenosine could increase GLUT1 mRNA expression through selective effects on the A<sub>2</sub>R. Cells were stimulated with the adenosine A<sub>2a</sub> receptor (A<sub>2a</sub>R)-selective agonist CGS21680, whose IC<sub>50</sub> for A<sub>2a</sub>R binding is 15 nmol/l as opposed to 2,600 nmol/l for A<sub>1</sub>R (23). CGS21680 increased GLUT1 mRNA levels in a dose-dependent manner (Fig. 3B) with significant increases observed as low as 10 nmol/l ( $168 \pm 14\%$ ,  $P < 0.01$ ) and maximal stimulation observed at 1,000 nmol/l ( $225 \pm 20\%$ ,  $P < 0.01$ ). In addition, the effects of NECA, an A<sub>2</sub>R agonist whose IC<sub>50</sub> for A<sub>2</sub>R binding is 16 nmol/l (23), were also evaluated. NECA increased GLUT1 mRNA expression in a dose-dependent manner (Fig. 3C) with significant increases observed as low as 10 nmol/l ( $183 \pm 13\%$ ,  $P < 0.01$ ) and maximal response observed at 10  $\mu$ mol/l ( $209 \pm 20\%$ ,  $P < 0.01$ ). NECA-induced GLUT1 mRNA expression was initially observed after 6 h (data not shown).

**Adenosine receptor antagonists inhibit the hypoxic induction of GLUT1 mRNA.** To determine whether the hypoxia-induced increase of GLUT1 mRNA could be prevented by blocking adenosine receptor activation, the effects of the A<sub>2a</sub>R antagonist CSC and adenosine-degrading enzyme, adenosine deaminase, were evaluated. The A<sub>2a</sub>R antagonist CSC, whose IC<sub>50</sub> is 25  $\mu$ mol/l for A<sub>1</sub>R binding and 100 nmol/l for A<sub>2</sub>R binding, inhibited the hypoxic response at 100 nmol/l, 1  $\mu$ mol/l, and 10  $\mu$ mol/l by  $40 \pm 8.1$  ( $P < 0.01$ ),  $37 \pm 13.3$  ( $P < 0.05$ ), and  $56 \pm 6.9\%$  ( $P < 0.01$ ), respectively. These are concentrations expected to be selective for blocking A<sub>2</sub>R (Fig. 4). Although not as potent as CSC, adenosine deaminase (10 U/ml) inhibited the hypoxic induction of GLUT1 mRNA by  $24 \pm 8.1\%$  ( $P < 0.05$ ).

**Hypoxia and adenosine agonists increase GLUT1 protein expression.** Hypoxia increased GLUT1 protein concentration in a time-dependent manner with statistically significant increases observed after 1 h and maximal stimulation observed after 24 h (Fig. 5). Hypoxia of 12- and 24-h duration increased GLUT1 protein levels by  $3.0 \pm 0.3$ - ( $P < 0.01$ ) and  $6.3 \pm 0.5$ -fold ( $P < 0.01$ ), respectively.

The A<sub>2</sub>R agonist NECA (100 nmol/l) increased GLUT1 protein in a time-dependent manner with statistically significant increases first observed after 6 h and a maximal stimulation of  $209 \pm 19.5\%$  ( $P < 0.01$ ) observed after 24 h (Fig. 6).

**Adenosine receptor antagonists inhibit hypoxia-induced GLUT1 protein expression.** To investigate whether hypoxia-induced increases of GLUT1 protein could be suppressed by blocking adenosine receptor activation, BRECs were exposed to the A<sub>2</sub>R-selective inhibitor CSC under normoxic and hypoxic conditions. CSC (10  $\mu$ mol/l) did not significantly effect GLUT1 protein levels under normoxic conditions (Fig. 7). Hypoxia induced a nearly twofold increase in GLUT1 protein ( $P < 0.01$ ), and this response was inhibited  $25 \pm 8.7\%$  ( $P < 0.05$ ) by CSC.

**Hypoxia-stimulated glucose transport activity is inhibited by an A<sub>2</sub>R antagonist.** Because hypoxia increases both GLUT1 mRNA and protein expression, the ability of hypoxia




FIG. 3. Adenosine receptor agonists increase GLUT1 mRNA expression. BRECs were exposed to the indicated concentrations of CPA (A), CGS21680 (B), and NECA (C) for 4.5 h under normoxic conditions followed by Northern blot analysis. A representative Northern blot using GLUT1 cDNA and control 36B4 probe (top) and quantitation of multiple experiments after normalization to the control signal (bottom) are shown. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .

conditions to alter glucose transport activity in BRECs was evaluated. Hypoxia increased 2-deoxyglucose uptake in a time-dependent manner with initial statistically significant increases observed after 6 h and a maximal  $6.3 \pm 0.6$ -fold ( $P < 0.01$ ) increase observed after 24 h (Fig. 8A).

Because  $A_2R$  antagonists inhibited hypoxia-induced GLUT1 mRNA (Fig. 4) and protein expression (Fig. 7), the effect of  $A_2R$  inhibition on hypoxia-induced glucose transport was evaluated (Fig. 8B). Hypoxia of 12-h duration increased glucose transport activity by  $207 \pm 31\%$  ( $P <$




FIG. 4. Adenosine receptor antagonists inhibit the hypoxia-induced expression of GLUT1 mRNA. Immediately before the initiation of hypoxia, BRECs were treated with the indicated dose of CSC or adenosine deaminase (10 U/ml). After 12 h, Northern blot analysis was performed. Quantitation of multiple experiments after normalization to the control signal are shown. \* $P < 0.05$ , \*\* $P < 0.01$ .

0.001). CSC (10  $\mu\text{mol/l}$ ), a specific antagonist of  $A_2R$ , had no significant effect on basal glucose transport but suppressed the hypoxia-induced glucose transport activity by 65% ( $P < 0.01$  vs. hypoxia alone).

**Hypoxic induction of GLUT1 mRNA is partially mediated by the cAMP-PKA pathway.** Stimulation of the  $A_1R$  inhibits adenylylase, whereas  $A_2R$  stimulation activates adenylylase, resulting in activation of cAMP-PKA pathway. To investigate whether adenylylase activation might induce GLUT1, cells were stimulated with the stable cAMP analog dibutyryl-cAMP, and GLUT1 mRNA expression was evaluated (Fig. 9A). Dibutyryl-cAMP (50  $\mu\text{mol/l}$ ) increased GLUT1 mRNA expression  $50 \pm 8.9\%$  ( $P < 0.05$ ) after 4 h. To determine whether cAMP activation of PKA was involved in the hypoxic induction of GLUT1 mRNA, cells were exposed to 12 h of hypoxia and various concentrations of H89, a selective inhibitor for PKA (Fig. 9B). H89 (20  $\mu\text{mol/l}$ ) inhibited the hypoxic induction of GLUT1 mRNA by  $42 \pm 8.5\%$  ( $P < 0.01$ ).  $A_1R$  activation stimulates phosphatidylinositol turnover leading to activation of PKC. However, 5  $\mu\text{mol/l}$  of the PKC inhibitor GFX did not inhibit the hypoxia-induced increase of GLUT1 mRNA (data not shown).

## DISCUSSION

Five distinct isoforms of mammalian facilitative glucose transporters have been cloned, each sharing 40–60% overall amino acid homology but differing in their distribution and functional properties (25). Among these glucose transporters, GLUT1 is the most widely distributed, regulates basal glucose uptake, and is reported to be concentrated in endothelial and epithelial cells that form occluding junctions (26). In the eye, the blood-retinal barrier is maintained by retinal capillary endothelial cells and retinal pigment epithelial cells. The predominant glucose transporter in these cells is GLUT1 (27,28).

A




FIG. 5. Hypoxia increases GLUT1 protein expression. BRECs were exposed to hypoxia for the indicated periods. Solubilized cell lysates were subjected directly to Western blot analysis using anti-GLUT1 antibody. A representative Western blot (A) and quantitation of multiple experiments (B) are shown. Results are expressed as GLUT1 protein expression (percent of control  $\pm$  SD). \* $P < 0.05$ , \*\* $P < 0.01$ .




FIG. 6. Adenosine agonist increases GLUT1 protein expression. BRECs were stimulated with 100 nmol/l of NECA for the indicated periods under normoxic conditions. Quantitation of multiple experiments are shown. \*\* $P < 0.01$ .




FIG. 7. Adenosine receptor antagonists inhibit the hypoxic induction of GLUT1 protein. Immediately before the initiation of hypoxia, BRECs were treated with CSC (10  $\mu\text{mol/l}$ ), and Western blot analysis was performed after 12 h. A representative Western blot (A) and quantitation of multiple experiments (B) are shown.

In the present study, we present data suggesting that hypoxia upregulates GLUT1 mRNA and protein expression, resulting in increased glucose uptake into capillary microvascular BRECs. Furthermore, hypoxia partially mediates this response through elevated concentrations of adenosine that activate  $A_2R$ , resulting in increased concentrations of cAMP and activation of PKA.

Hypoxic induction of glucose uptake through increased expression of GLUT1 is supported by several findings. Cells exposed to 0.5% oxygen increased GLUT1 mRNA levels 8.9-fold after 12 h, and GLUT1 protein concentrations increased 6.3-fold after 24 h. There was a concurrent 6.3-fold increase in 2-deoxyglucose uptake after 24 h. Hypoxia-induced GLUT1 mRNA expression has been reported in bovine aortic endothelial cells (11) and smooth muscle cell (29). In the large vessel endothelial cells (11), stimulation (ninefold) was similar to that observed in this study for microvascular BRECs even though other receptor-mediated characteristics are known to differ (21,30). In contrast, the stimulation in L6 muscle cells was sixfold (29). Reinstitution of normoxia also reversed the hypoxia-induced expression of GLUT1 mRNA as has been demonstrated for other oxygen-sensitive adenosine-mediated genes such as VEGF (31).

Hypoxia is known to induce substantial increases in adenosine (15), mainly due to decreased recycling of adenosine to AMP by adenosine kinase (15). Adenosine can mediate multiple cellular functions through cell surface adenosine receptors. Indeed, the regulation of erythropoietin (19,32), VEGF, and its receptor KDR are regulated in this manner (17,18,33,34). Adenosine mediates its effects through cell surface receptors, which act via G proteins and couple to adenylylase and ion channels (35,36). Adenosine receptors possess seven transmembrane helical structures (37) and are categorized as  $A_1$ ,  $A_{2a}$ ,  $A_{2b}$ ,  $A_3$ , and possibly other  $A_1$






FIG. 8. Hypoxia stimulates glucose transport activity that is inhibited by an  $A_2R$ -selective antagonist. BRECs were exposed to hypoxia for the indicated duration, and  $^3\text{H}$ -deoxyglucose uptake was measured (A). Immediately before the initiation of hypoxia, BRECs were exposed to 10  $\mu\text{mol/l}$  CSC, and  $^3\text{H}$ -deoxyglucose uptake was measured after 12 h (B).



**FIG. 9.** cAMP stimulates GLUT1 mRNA expression, while inhibition of PKA suppresses the hypoxic induction of GLUT1 mRNA expression. BRECs were stimulated under normoxic conditions with 100  $\mu\text{mol/l}$  dibutyryl-cAMP for 6 h, and GLUT1 mRNA expression was assessed by Northern blot analysis (A). Immediately before the initiation of hypoxia, BRECs were treated with 20  $\mu\text{mol/l}$  H89 (a selective PKA inhibitor), and Northern blot analysis was performed after 12 h (B). Representative Northern blots using GLUT1 cDNA and control 36B4 probe (top and inset) and quantitation of multiple experiments after normalization to the control signal (bottom) are shown. \* $P < 0.05$ .

subtypes by pharmacological interaction with a variety of agonists and antagonists (36).

The selective involvement of  $A_2R$  in mediating the hypoxic induction of GLUT1 is supported by several findings. CPA, an  $A_1R$  agonist, showed little effect at concentrations up to 1,000 nmol/l, but it increased GLUT1 mRNA expression at higher concentrations (Fig. 3A). Because the  $IC_{50}$ s for  $A_1R$  and  $A_2R$  are 1.0 and 680 nmol/l, respectively (23,24), these data suggest that hypoxic induction of GLUT1 mRNA expression is partially mediated through  $A_2R$ . In contrast, the  $A_2R$ -selective agonist CGS21680 increased GLUT1 mRNA levels at concentrations as low as 10 nmol/l (Fig. 3B). Because the  $IC_{50}$  of this agonist are 15 and 2,600 nmol/l for  $A_2R$  and  $A_1R$ , respectively (23), these data again suggest that the hypoxic response is partially mediated by the  $A_2R$ .

There are two  $A_2R$  subtypes,  $A_{2a}R$  and  $A_{2b}R$ . CGS21680 is a more potent agonist of  $A_{2a}R$  than of  $A_{2b}R$ , while NECA stimulates both equally. Because both CGS21680 (Fig. 3B) and NECA (Fig. 3A) had very similar effects, a predominant role of  $A_{2a}R$  is suggested.

The role of  $A_2R$  in mediating the hypoxic induction of GLUT1 mRNA is further supported by the ability of CSC (an  $A_{2a}R$ -selective antagonist) and adenosine desaminase (an enzyme that degrades adenosine) to inhibit this response (Fig. 4). Because adenosine desaminase does not enter intact cells, and because its effect was not greater than that

observed for the  $A_{2a}R$ -selective antagonist CSC, the role of  $A_{2a}R$  and extracellular adenosine stimulation is further supported. Finally, GLUT1 protein expression responded in a similar manner to GLUT1 mRNA expression with regard to hypoxia (Fig. 5), adenosine receptor stimulation (Fig. 6), and  $A_2R$  inhibition (Fig. 7).

The role of cAMP and PKA in the hypoxia-induced expression of GLUT1 is supported by several findings. Activation of  $A_2R$  increases cAMP concentrations, whereas activation of  $A_1R$  decreases them (35). Our previous studies have shown that in retinal vascular cells, hypoxia and  $A_2R$  agonists increase intracellular concentrations of cAMP, while  $A_1R$  agonists do not inhibit forskolin-induced cAMP expression (18). In the present study, the finding that cAMP increases GLUT1 mRNA supports the role of  $A_2R$  in the hypoxia-mediated induction of GLUT1. The involvement of PKA is supported by inhibition of hypoxia-induced GLUT1 expression by H89, a selective inhibitor of PKA (Fig. 9B). The manner in which PKA activates GLUT1 awaits further investigation.

Hypoxia also stimulates PKC (38,39) and *src*-related pathways (40,41). However, the PKC-selective inhibitor GFX did not inhibit the hypoxic stimulation of GLUT1 expression, suggesting that the PKC pathway does not have a major role in hypoxic regulation of this gene in BRECs. This finding again implicates mediation through  $A_2R$  rather than  $A_1R$ , since  $A_1R$  stimulation stimulates the PKC pathway (35).

Overall, in BRECs, GLUT1 regulation by hypoxia is similar to that of VEGF, as we have previously reported (18), in that adenosine, A<sub>2</sub>R, and subsequent stimulation of the cAMP-PKA pathway are involved. Concerted regulation of VEGF and GLUT1 has been reported in response to ischemia and hypoxia due to mRNA stabilization (12). Three adenylate-uridylylate-rich RNA elements (AREs) in the 3'-untranslated region (UTR) of VEGF mRNA form a hypoxia-inducible RNA-protein complex. An RNA-protein complex with similar sequence and protein binding characteristics has been identified for GLUT1 (14). The increase in mRNA stability of GLUT1 in response to agonists such as phorbol ester, cAMP, and tumor necrosis factor- $\alpha$  is correlated with increased binding of specific proteins to AREs in a region of the GLUT1 3'-UTR that normally directs rapid mRNA turnover (42). Thus, it is possible that hypoxia may increase protein binding to the AREs in the 3'-UTR of these genes by an adenosine-, A<sub>2</sub>R-, and cAMP-PKA-mediated pathway. Hypoxia can also induce transcriptionally mediated regulation of genes, such as VEGF (43–45), GLUT1 (13), and glycolytic enzymes (46). Hypoxia inducible factor-1 and its binding elements mediate this response. Other factors such as AP1 (47), SP1 (48), and the nuclear factor-IL6 site (49) are also involved in hypoxic gene regulation. Further studies will be required to determine the detailed mechanisms by which adenosine-mediated activation of the cAMP-PKA signaling pathway increases GLUT1 mRNA.

In summary, we have demonstrated that hypoxia upregulates glucose transport activity in microvascular BRECs partially through an adenosine-mediated increase of GLUT1 mRNA and protein expression. Furthermore, the data suggest that adenosine is signaling through A<sub>2</sub>R, resulting in increased cAMP levels and PKA activation. One could postulate that the retinal nonperfusion characteristic of diabetic retinopathy increases glucose transport, inducing elevated intracellular glucose concentrations and resulting in additional microvascular compromise that further worsens diabetic retinopathy.

#### ACKNOWLEDGMENTS

Financial support for this work was provided in part by National Institutes of Health Grants EY09178 (G.L.K.) and EY10827 (L.P.A.). The Joslin Diabetes Center is the recipient of National Institutes of Health Diabetes and Endocrinology Research Center Grant 36836.

The authors are grateful to Dr. Barbara M. Kern for the generous gift of Human GLUT1 cDNA probe and to Joan Taylor and Ann Kopple for assistance in manuscript preparation. Present address for H.T. is the Department of Ophthalmology and Visual Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

#### REFERENCES

- Krolewski AS, Warram JH, Rand LI, Kahn CR: Epidemiologic approach to the etiology of type 1 diabetes mellitus and its complications. *N Engl J Med* 309:1390–1398, 1987
- Piart J: Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. *Diabetes Care* 1:168–188, 1978
- The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 329:977–986, 1993
- King GL, Johnson S, Wu G: Possible growth modulators involved in the pathogenesis of diabetic proliferative retinopathy. In *Growth Factors in Health and Diseases*. Westermarck B, Betscholtz C, Hokfelt B, Eds. Amsterdam, Elsevier, 1990, p. 303–317
- Greene DA, Lattimer SA, Sima AA: Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. *N Engl J Med* 316:599–606, 1987
- Pulgliese G, Tilton R, Williamson JR: Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular complications. *Diabetes Metab Rev* 7:21–35, 1991
- Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. *N Engl J Med* 318:1315–1321, 1988
- Mandarino LJ, Finlayson J, Hassel JR: High glucose downregulates glucose transport activity in retinal capillary pericytes but not endothelial cells. *Invest Ophthalmol Vis Sci* 35:964–972, 1994
- Kaiser N, Sasson S, Feener EP, Boukobza-Vardi N, Higashi S, Moller DE, Davidheiser S, Przybylski RJ, King GL: Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. *Diabetes* 42:80–89, 1993
- Cartee GD, Douen AG, Ramlal T, Klip A, Holloszy JO: Stimulation of glucose transport in skeletal muscle by hypoxia. *J Appl Physiol* 70:1593–1600, 1991
- Loike JD, Cao L, Brett J, Ogawa S, Silverstein SC, Stern D: Hypoxia induces glucose transporter expression in endothelial cells. *Am J Physiol* 263:C326–C333, 1992
- Stein I, Neeman M, Shweiki D, Itin A, Keshet E: Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. *Mol Cell Biol* 15:5363–5368, 1995
- Ebert BL, Firth JD, Ratcliffe PJ: Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct *cis*-acting sequences. *J Biol Chem* 270:29083–29089, 1995
- Levy AP, Levy NS, Goldberg MA: Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. *J Biol Chem* 271:25492–25497, 1996
- Bontemps F, Mimouni M, Van den Berghe G: Mechanisms of elevation of adenosine levels in anoxic hepatocytes. *J Biochem* 290:671–677, 1993
- Sen H, Capoor S, Howard M, Adkins J, Jacobson M: Vitreous adenosine levels in a porcine model of retinal ischemia. *Invest Ophthalmol Vis Sci* 37 (Suppl.):S658, 1996
- Takagi H, King GL, Ferrara N, Aiello LP: Hypoxia regulates vascular endothelial growth factor receptor KDR/FK gene expression through adenosine A<sub>2</sub> receptor in retinal capillary endothelial cells. *Invest Ophthalmol Vis Sci* 37:1311–1321, 1996
- Takagi H, King GL, Robinson GS, Ferrara N, Aiello LP: Hypoxic-induction of vascular endothelial growth factor (VEGF) is mediated by adenosine, adenosine A<sub>2</sub> receptors, and cAMP-dependent protein kinase A in retinal microvascular pericytes and vascular endothelial cells. *Invest Ophthalmol Vis Sci* 37:2165–2176, 1996
- Goldberg MA, Schneider TJ: Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. *J Biol Chem* 269:4355–4359, 1994
- Nakashima J, Ohigashi T, Brookins JW, Beckman BS, Agrawal KC, Fisher JW: Effects of 5'-N-ethylcarboxamidoadenosine (NECA) on erythropoietin production. *Kidney Int* 44:734–740, 1993
- King GL, Goodman S, Buzney S, Moses A: Receptors and growth-promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta. *J Clin Invest* 75:1028–1036, 1985
- Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-PhOH-chloroform extraction. *Anal Biochem* 162:156–159, 1987
- Research Biochemical International: *Research Biochemical International 1995 Handbook*. Natick, MA, Research Biochemical International, 1995
- Burns RF, Lu GH, Pugsley TA: Characterization of the A<sub>2</sub> adenosine receptor labeled by [<sup>3</sup>H]NECA in rat striatal membrane. *Mol Pharmacol* 29:331–346, 1986
- Maher F, Vannucci SJ, Simpson IA: Glucose transporter proteins in brain. *Faseb J* 8:1003–1011, 1994
- Harik SI, Kalaria RN, Whitney PM, Andersson L, Lundahl P, Ledbetter SR, Perry G: Glucose transporters are abundant in cells with "occluding" junctions at the blood-eye barriers. *Proc Natl Acad Sci U S A* 87:4261–4264, 1990
- Takata K, Kasahara T, Kasahara M, Ezaki O, Hirano H: Ultracytochemical localization of the erythrocyte/HepG2-type glucose transporter (GLUT1) in cells of the blood-retinal barrier in the rat. *Invest Ophthalmol Vis Sci* 33:377–383, 1992
- Takagi H, Tanihara H, Seino Y, Yoshiura N: Characterization of glucose transporter in cultured human retinal pigment epithelial cells: gene expression and effect of growth factors. *Invest Ophthalmol Vis Sci* 35:170–177, 1994



29. Bashan N, Burdett E, Hundal HS, Klip A: Regulation of glucose transport and GLUT1 glucose transporter expression by O<sub>2</sub> in muscle cells in culture. *Am J Physiol* 262:C682-C690, 1992
30. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL: Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. *Diabetes* 44:98-103, 1995
31. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA: Hypoxic regulation of vascular endothelial growth factor in retinal cells. *Arch Ophthalmol* 113:1538-1544, 1995
32. Nakashima J, Brookins J, Beckman B, Fisher JW: Increased erythropoietin secretion in human hepatoma cells by N<sup>6</sup>-cyclohexyladenosine. *Am J Physiol* 261:C455-C460, 1991
33. Hashimoto E, Kage K, Ogita T, Nakaoka T, Matsuoka R, Kira Y: Adenosine as an endogenous mediator of hypoxia for induction of vascular endothelial growth factor mRNA in U-937 cells. *Biochem Biophys Res Commun* 204:318-324, 1994
34. Fischer S, Sharma HS, Karliczek GF, Schaper W: Expression of vascular permeability factor/vascular endothelial growth factor in pig cerebral microvascular endothelial cells and its upregulation by adenosine. *Brain Res Mol Brain Res* 28:141-148, 1995
35. Collis MG, Hourani SMO: Adenosine receptor subtypes. *Tips Reviews* 14:360-366, 1993
36. Tucker AL, Linden J: Cloned receptors and cardiovascular responses to adenosine. *Cardiovasc Res* 27:62-67, 1993
37. Libert F, Parmentier M, Lefort A: Selective amplification and cloning of four new members of the G-protein coupled receptor family. *Science* 244:569-572, 1989
38. Yavin E, Inserte-Igual J, Gil S: Ischemia-triggered translocation and inactivation of protein kinase C isoforms in the fetal brain. *J Neurochem* 65:2594-2602, 1995
39. Yao A, Takahashi T, Aoyagi T, Kinugawa K, Kohmoto O, Sugiura S, Serizawa T: Immediate-early gene induction and MAP kinase activation during recovery from metabolic inhibition in cultured cardiac myocytes. *J Clin Invest* 96:69-77, 1995
40. Koong AC, Chen EY, Mivechi NF, Denko NC, Stambrook P, Giaccia AJ: Hypoxic activation of nuclear factor-κB is mediated by a *ras* and *raf* signaling pathway and does not involve MAP kinase (ERK1 or ERK2). *Cancer Res* 54:5273-5279, 1994
41. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP: Hypoxic induction of human vascular endothelial growth factor expression through *c-src* activation. *Nature* 375:577-581, 1995
42. Stephens JM, Carter BZ, Pekala PH, Malter JS: Tumor necrosis factor-α-induced glucose transporter (GLUT1) mRNA stabilization in 3T3-L1 preadipocytes: regulation by the adenosine-uridine binding factor. *J Biol Chem* 267:8336-8341, 1992
43. Levy AP, Levy NS, Wegner S, Goldberg MA: Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. *J Biol Chem* 270:13333-13340, 1995
44. Liu Y, Cox SR, Morita T, Kourembanas S: Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells: identification of a 5' enhancer. *Circ Res* 77:638-643, 1995
45. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. *Mol Cell Biol* 16:4604-4613, 1996
46. Semenza GL, Jiang B-H, Leung SW, Passantino R, Concordet J-P, Maire P, Gialongo A: Hypoxia responsive elements in the aldose A, enlase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. *J Biol Chem* 271:32529-32537, 1996
47. Norris ML, Millhorn DE: Hypoxia-induced protein binding to O<sub>2</sub>-responsive sequences on the tyrosine hydroxylase. *J Biol Chem* 270:23774-23779, 1995
48. Ikeda E, Achen MG, Breier G, Risau W: Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. *J Biol Chem* 270:19761-19766, 1995
49. Yan SF, Tritto I, Pinsky D, Liao H, Huang J, Fuller G, Brett J, May L, Stern D: Induction of interleukin-6 (IL-6) by hypoxia in vascular cells: central role of the binding site for nuclear factor-IL-6. *J Biol Chem* 270:11463-11471, 1995